EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference

Print
| Source: Immune Pharmaceuticals Inc
multilang-release
EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on     
                             Healthcare Conference                              

TARRYTOWN, N.Y., Nov. 28  -- EpiCept Corporation (Nasdaq and OMX Nordic         
Exchange: EPCT) today announced that Jack Talley, President and CEO, will       
present a company overview at the BMO Capital Markets Focus on Healthcare       
Conference on December 5, 2007 at 11:00 a.m. Eastern Time.  The conference will 
be held at The Millennium Broadway Hotel in New York City on December 4th and   
5th.  Mr. Talley will present a company overview.                               
    (Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )            
The presentation will be available live via webcast on December 5, 2007.  The   
webcast can be accessed by visiting the Company's website at www.epicept.com.  A
replay of the presentation will be available following the event.               

    About EpiCept Corporation                                                   
EpiCept is focused on unmet needs in the treatment of pain and cancer. The      
Company has a staged portfolio of pharmaceutical product candidates with several
pain therapies in late-stage clinical trials, and a lead oncology compound (for 
acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial;
a marketing authorization application for this compound has been submitted in   
Europe. EpiCept is based in Tarrytown, N.Y., and its research and development   
team in San Diego is pursuing a drug discovery program focused on novel         
approaches to apoptosis.                                                        

    Forward-Looking Statements                                                  
This news release and any oral statements made with respect to the information  
contained in this news release, contains forward-looking statements within the  
meaning of the Private Securities Litigation Reform Act of 1995. Such           
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not   
statements of historical fact. These statements are based on EpiCept's current  
expectations and are subject to risks and uncertainties that could cause actual 
results or developments to be materially different from historical results or   
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially      
include: the risk that Ceplene will not receive regulatory approval or marketing
authorization in the EU or that Ceplene, if approved, will not achieve          
significant commercial success, the risk that Myriad's development of Azixa(TM)*
will not be successful, the risk that Azixa will not receive regulatory approval
or achieve significant commercial success, the risk that EpiCept will not       
receive any significant payments under its agreement with Myriad, the risk that 
the development of the Company's other apoptosis product candidates will not be 
successful, the risk that its ASAP technology will not yield any successful     
product candidates, the risk that clinical trials for NP-1 or EPC 2407 will not 
be successful, that NP-1 or EPC 2407 will not receive regulatory approval or    
achieve significant commercial success, the risk that the Company's other       
product candidates that appeared promising in early research and clinical trials
do not demonstrate safety and/or efficacy in larger-scale or later stage        
clinical trials, the risk that EpiCept will not obtain approval to market any of
its product candidates, the risks associated with reliance on additional outside
financing to meet its capital requirements, the risks associated with dependence
upon key personnel, the risks associated with reliance on collaborative partners
and others for further clinical trials, development, manufacturing and          
commercialization of its product candidates; the cost, delays and uncertainties 
associated with its scientific research, product development, clinical trials   
and regulatory approval process; its history of operating losses since          
inception; competition; litigation; risks associated with prior material        
weaknesses in internal controls; and risks associated with the Company's ability
to protect its intellectual property. These factors and other material risks are
more fully discussed in EpiCept's periodic reports, including its reports on    
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange
Commission. You are urged to carefully review and consider the disclosures found
in EpiCept's filings which are available at www.sec.gov or at www.epicept.com.  
You are cautioned not to place undue reliance on any forward-looking statements,
any of which could turn out to be wrong due to inaccurate assumptions, unknown  
risks or uncertainties or other risk factors.                                   

    EPCT-GEN                                                                    

    *Azixa is a registered trademark of Myriad Genetics, Inc.                   

SOURCE  EpiCept Corporation                                                     
    -0-                             11/28/2007                                  
/CONTACT:  Robert W. Cook, EpiCept Corporation, +1-914-606-3500,                
rcook@epicept.com; Investors, Kim Sutton Golodetz, +1-212-838-3777,             
kgolodetz@lhai.com or Bruce Voss, +1-310-691-7100, bvoss@lhai.com, both of      
Lippert/Heilshorn & Associates; or Media, Greg Kelley, Feinstein Kean           
Healthcare, +1-617-577-8110, gregory.kelley@fkhealth.com /                      
    /Photo:  NewsCom:  http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO  
             AP Archive:  http://photoarchive.ap.org                            
             PRN Photo Desk, photodesk@prnewswire.com /                         
    /Web site:  http://www.epicept.com /                                        
    (EPCT)